AMPLIA THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.065 AUD | +1.56% |
|
+6.56% | -18.75% |
| Apr. 16 | Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing | MT |
| Mar. 27 | Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II | MT |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 17.15 | 5.743 | 3.855 | 28.07 | 28.11 | 16.49 |
| Enterprise Value (EV) 1 | 14.92 | 4.502 | 2.747 | 26.22 | 15.6 | 9.51 |
| P/E ratio | -3.99 x | -2.98 x | -1.27 x | -10.8 x | -5.79 x | -2.64 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 29.6 x | 114 x | 113 x | 18.3 x | 14.2 x | 13.9 x |
| EV / Revenue | 25.7 x | 89.2 x | 80.3 x | 17.1 x | 7.87 x | 7.99 x |
| EV / EBITDA | -3.47 x | -2.38 x | -1.24 x | -11.2 x | -4.29 x | -1.52 x |
| EV / FCF | -7.3 x | -15.7 x | -2.18 x | -12.5 x | -5.07 x | -3.18 x |
| FCF Yield | -13.7% | -6.39% | -45.9% | -8.02% | -19.7% | -31.4% |
| Price to Book | 7.25 x | 0.66 x | 0.45 x | 2.72 x | 1.29 x | 1.04 x |
| Nbr of stocks (in thousands) | 22,563 | 41,023 | 66,463 | 107,973 | 193,854 | 194,006 |
| Reference price 2 | 0.7600 | 0.1400 | 0.0580 | 0.2600 | 0.1450 | 0.0850 |
| Announcement Date | 6/20/18 | 6/27/19 | 6/25/20 | 6/29/21 | 5/29/22 | 5/30/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.5803 | 0.0505 | 0.0342 | 1.534 | 1.983 | 1.189 |
| EBITDA 1 | -4.304 | -1.889 | -2.222 | -2.339 | -3.64 | -6.276 |
| EBIT 1 | -4.325 | -1.89 | -2.223 | -2.34 | -3.644 | -6.286 |
| Operating Margin | -745.24% | -3,744.98% | -6,495.43% | -152.6% | -183.72% | -528.45% |
| Earnings before Tax (EBT) 1 | -4.298 | -1.87 | -2.219 | -2.281 | -3.644 | -6.242 |
| Net income 1 | -4.298 | -1.87 | -2.219 | -2.281 | -3.644 | -6.242 |
| Net margin | -740.59% | -3,704.79% | -6,484.57% | -148.75% | -183.74% | -524.8% |
| EPS 2 | -0.1905 | -0.0470 | -0.0458 | -0.0241 | -0.0250 | -0.0322 |
| Free Cash Flow 1 | -2.044 | -0.2876 | -1.261 | -2.103 | -3.074 | -2.986 |
| FCF margin | -352.28% | -569.76% | -3,683.47% | -137.11% | -155% | -251.02% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/20/18 | 6/27/19 | 6/25/20 | 6/29/21 | 5/29/22 | 5/30/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 2.23 | 1.24 | 1.11 | 1.85 | 12.5 | 6.98 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -2.04 | -0.29 | -1.26 | -2.1 | -3.07 | -2.99 |
| ROE (net income / shareholders' equity) | -95.6% | -33.9% | -25.7% | -24.1% | -22.6% | -33.1% |
| ROA (Net income/ Total Assets) | -53.1% | -20% | -15.2% | -14.6% | -12.9% | -18.2% |
| Assets 1 | 8.094 | 9.366 | 14.62 | 15.59 | 28.29 | 34.3 |
| Book Value Per Share 2 | 0.1000 | 0.2100 | 0.1300 | 0.1000 | 0.1100 | 0.0800 |
| Cash Flow per Share 2 | 0.1000 | 0.0300 | 0.0200 | 0.0200 | 0.0800 | 0.0500 |
| Capex 1 | 0 | 0 | - | 0.01 | 0.01 | 0.02 |
| Capex / Sales | 0.76% | 6.32% | - | 0.35% | 0.73% | 1.48% |
| Announcement Date | 6/20/18 | 6/27/19 | 6/25/20 | 6/29/21 | 5/29/22 | 5/30/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -18.75% | 8.22M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ATX Stock
- Financials Amplia Therapeutics Limited
